A phase III randomized, controlled study to assess the immunogenicity and tolerability of DTPw-HBV-Hib, a liquid pentavalent vaccine in Indian infants

Vaccine

Volumn 29, Issue 13, 2011, Pages 2359-2364

  Sharma, Hitt ^a   Yadav, Sangita ^b   Lalwani, Sanjay ^c   Gupta, Vijay ^d   Kapre, Subhash ^a   Jadhav, Suresh ^a   Chakravarty, Anita ^b   Parekh, Sameer ^a   Palkar, Sonali ^c  

^a Serum Institute of India Ltd   (India)

^b MAULANA AZAD MEDICAL COLLEGE   (India)

^c Bharati Vidyapeeth's Medical College   (India)

^d DR RAM MANOHAR LOHIA HOSPITAL   (India)

Author keywords

Combination vaccine; Immunogenicity; India; Liquid pentavalent vaccine; Safety

Indexed keywords

ALUMINUM PHOSPHATE; DIPHTHERIA ANTIBODY; DIPHTHERIA PERTUSSIS TETANUS HAEMOPHILUS INFLUENZAE TYPE B HEPATITIS B VACCINE; DIPHTHERIA TOXOID CRM197; EASYFIVE; IMMUNOLOGICAL ADJUVANT; PENTAVAC; TETANUS ANTIBODY; UNCLASSIFIED DRUG;

APPETITE DISORDER; ARTICLE; BIRTH WEIGHT; BLOOD SAMPLING; CLINICAL ASSESSMENT; CONJUGATION; DIARRHEA; DIPHTHERIA; DRUG COST; DRUG FEVER; DRUG TOLERABILITY; FEMALE; HAEMOPHILUS INFECTION; HEPATITIS B; HUMAN; IMMUNOGENICITY; INDIAN; INFANT; INFLUENZA VACCINATION; INJECTION SITE NODULE; INJECTION SITE PAIN; INJECTION SITE SWELLING; LIMB MOVEMENT; MAJOR CLINICAL STUDY; MALE; MASS IMMUNIZATION; MULTICENTER STUDY; OPEN STUDY; PASSIVE IMMUNIZATION; PERTUSSIS; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROTECTION; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE DRUG DOSE; SKIN REDNESS; TETANUS; TETANUS PROPHYLAXIS; TREATMENT RESPONSE; VOMITING;

ANTIBODIES, BACTERIAL; DIPHTHERIA-TETANUS-PERTUSSIS VACCINE; FEMALE; HAEMOPHILUS VACCINES; HEPATITIS B ANTIBODIES; HEPATITIS B VACCINES; HUMANS; INDIA; INFANT; MALE; PAIN; VACCINES, COMBINED;

EID: 79952360694     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.01.054     Document Type: Article

References (26)

1. Aristegui J., Usonis V., Coovadia H., Riedmann S., Win K.M., Gatchalian, et al. Facilitating the WHO expanded program of immunization: the clinical profile of a combined diphtheria, tetanus, pertussis, hepatitis B and Haemophilus influenzae b vaccine. Int J Infect Dis 2003, 7:143-151.
2. Kohl K.S., Walop W., Gidudu J., Ball L., Halperin S., Hammer S.J., et al. Swelling at or near injection site: case definition and guidelines for collection, analysis and presentation of immunization safety data. Vaccine 2007, 25:5858-5874.
3. Rothstein E., Kohl K.S., Ball L., Halperin S.A., Halsey N., Hammer S.J., et al. Nodule at injection site as an adverse event following immunization: case definition and guidelines for data collection, analysis and presentation. Vaccine 2004, 22:575-585.
4. Marcy S.M., Kohl K.S., Dagan R., Nalin D., Blum M., Jones M.C., et al. Fever as an adverse event following immunization: case definition and guidelines of data collection, analysis and presentation. Vaccine 2004, 22:551-556.
5. World Health Organization Position paper on diphtheria vaccine. Wkly Epidemiol Rec 2006, 81(3):24-32.
6. World Health Organization Position paper on tetanus vaccine. Wkly Epidemiol Rec 2006, 81(20):198-208.
7. World Health Organization Position paper on hepatitis B vaccines. Wkly Epidemiol Rec 2004, 79(28):255-263.
8. Kayhty H., Peltola H., Karanko V., Makela P.H. The protective level of serum antibodies to the capsular polysaccharide of Haemophilus influenzae type b. J Infect Dis 1983, 147:1100.
9. World Health Organization Pertussis vaccines: WHO position paper. Wkly Epidemiol Rec 2010, 85:385-400.
10. WHO Technical Report Series No. 941, Annex 6. Recommendations for whole-cell pertussis vaccine; 2007.
11. Peltola H. Worldwide Haemophilus Influenzae type b disease at the beginning of the 21st century: global analysis of the disease burden 25 years after the use of the polysaccharide vaccine and a decade the advent of conjugates. Clin Microbiol Rev 2000, 13:302-317.
12. Peltola H. Spectrum and burden of severe Haemophilus Influenzae type b disease in Asia. Bull WHO 1999, 77:878-887.
13. World Health Organization Position paper on Haemophilus influenzae type b conjugate vaccines. Wkly Epidemiol Rec 2006, 81(47):445-452.
14. Indian Academy of Pediatrics Committee On Immunization (IAPCOI) Consensus recommendations on immunization. Indian Pediatr 2008, 45:635-648.
15. Insel R.A. Potential alterations in immunogenecity in combining or simultaneously administering vaccine components. Ann NY Acad Sci 1995, 754:35.
16. Morefield G.L., HogenEsch H., Robinson J.P., Hem S.L. Distribution of adsorbed antigen in mono-valent and combination vaccines. Vaccine 2004, 22:1973-1984.
17. Rao R., Dhingra M.S., Bavdekar S., Behera N., Daga S.R., Dutta A.K., et al. A comparison of immunogenicity and safety of indigenously developed liquid (DTwP-HB-Hib) pentavalent combination vaccine (Shan 5) with Easyfive (liq) and TritanrixHB+Hiberix (lyo) in Indian infants administered according to the EPI schedule. Hum Vaccin 2009, 5(6):425-429.
18. Ali S.S., Chandrashekar S.R., Rao S., Singh M., Bansal R.K., Sharma D.R., et al. A multicenter, prospective, open-label, non-comparative study to evaluate the immunogenicity and tolerance of a new fully liquid pentavalent vaccine (DTwP-HepB-Hib vaccine). Hum Vaccin 2007, 3(4):116-121.
19. Tregnaghi M., López P., Rocha C., Rivera L., David M.P., Rüttimann R., Schuerman L. A new DTPw-HB/Hib combination vaccine for primary and booster vaccination of infants in Latin America. Rev Panam Salud Publica/Panam Am J Public Health 2006, 19(3).
20. Kanra G., Kara A., Demiralp O., Contorni M., Hilbert A.K., Spy C., et al. Safety and immunogenicity of a new fully liquid DTPw-HepB-Hib combination vaccine in infants. Hum Vaccin 2006, 2(4):155-160.
21. Santos J.I., Martin A., De Leon T., Rivera L., Gaitan M.E., Del Rio C., Oselka G., Cervantes Y., Rubio P., Clemens S.A., de Mendonca J.S. DTPw-HB and Hib primary and booster vaccination: combined versus separate administration to Latin American children. Vaccine 2002, 20:1887-1893.
22. Faingezicht I., Avila-Aguerro M.L., Cervantes Y., Fourneau M., Costa Clemens S.A. Primary and booster vaccination with DTPw-HB/Hib pentavalent vaccine in Costa Rican children who had received a birth dose of hepatitis B vaccine. Rev Panam Salud Publica 2002, 12(4):247-257.
23. Win K.M., Aye M., Htay-Htay H., et al. Comparison of separate and mixed administration of DPTw-HBV and Hib vaccines: immunogenecity and reactogenecity profiles. Int J Infect Dis 1997, 2:79-84.
24. Aristegui J., Garrote E., Gonzalez A., Arrate J.-P., Perez A., Vandepapeliere P. Immune response to a combined hepatitis B, diphtheria, tetanus and whole cell pertussis vaccine administered to infants at 2, 4 and 6 months of age. Vaccine 1997, 15:7-9.
25. Department of Vaccines and Biologicals, WHO Vaccines and biologicals update 2000, vol. 34. Department of Vaccines and Biologicals, WHO.
26. Supplementary information on vaccine safety. Part 2: background rates of adverse events following immunization. WHO/V&B/00.36; 2000.